Vallon Pharmaceuticals, Inc.

NasdaqCM:VLON Voorraadrapport

Marktkapitalisatie: US$5.4m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Vallon Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

-25.1%

Groei van de winst

15.5%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroei-100.0%
Rendement op eigen vermogen-299.9%
Nettomargen/a
Laatste winstupdate31 Dec 2022

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Vallon Pharmaceuticals reports Q2 results

Jul 28

We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate

Dec 15
We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate

We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully

Aug 17
We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully

Will Vallon Pharmaceuticals (NASDAQ:VLON) Spend Its Cash Wisely?

May 17
Will Vallon Pharmaceuticals (NASDAQ:VLON) Spend Its Cash Wisely?

Opbrengsten en kosten

Hoe Vallon Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:VLON Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 220-761
30 Sep 220-954
30 Jun 220-954
31 Mar 220-955
31 Dec 210-945
30 Sep 210-834
30 Jun 210-725
31 Mar 210-625
31 Dec 200-514
30 Sep 200-413
30 Jun 200-413
31 Mar 200-412
31 Dec 190-312

Kwaliteitswinsten: VLON is currently unprofitable.

Groeiende winstmarge: VLON is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: VLON is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.

Versnelling van de groei: Unable to compare VLON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: VLON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.6%).


Rendement op eigen vermogen

Hoge ROE: VLON has a negative Return on Equity (-299.91%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden